Tom Cowap

Tom Cowap
T: +44 (0) 20 7246 0512
E: tom.cowap@alantra.com

Tom is a director and has eight years' experience in finance, M&A and transaction services.

Tom has supported the delivery of a number of transactions including advising Spectris plc on its £163m acquisition of Concept Life Sciences; ConSol Partners on an investment in the business by Empresaria, the debt-funded management buy-out of XLN Business Services, the growth capital investment in Aero Technics, and the sales of Steelite International to US-based PNC Riverarch Capital, CP Electronics to Legrand, the ARX Group to CareFusion International and Shimtech Industries to Auctus Industries.

Tom is also a member of Alantra's Healthcare sector team. He has a particular focus on the pharmaceutical sector and is one of the authors of the Alantra Pharma Fast 50

A first class honours graduate in Finance from Durham University, Tom qualified as a chartered accountant with PwC. After spending two years within their general audit division, he moved into transaction services where he advised on both buy and sell-side transactions. Tom joined Alantra in 2013.

Away from work, Tom is a Lieutenant in the Territorial Army and competes at a national level in Brazilian Jiu Jitsu.

 

Alantra appoints experienced partner to head up its UK Real Estate & Hospitality team

Alantra has appointed Hoong Wey Woon as a Partner to head up its UK Real Estate & Hospitality team.  

Alantra advises Strong Roots on securing over €15.5m of investment

Alantra advises Strong Roots, one of the UK’s fastest-growing food companies, on securing over €15.5m of investment 

Alantra advises i2S on its sale to Gfi Informatique

Alantra advises Portuguese IT firm, i2S, on its sale to Gfi Informatique 

Alantra expands its technology sector team with two senior appointments

Alantra has expanded its Technology Media and Telecoms (TMT) sector team with two senior appointments. James Chapman-Andrews joins as Partner and Head of UK TMT and Simon Devonshire OBE, joins as Technology Industry Adviser.  

Alantra advises on sale of 3P Biopharmaceuticals to Keensight Capital

We advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European growth private equity fund with deep expertise in healthcare.